2015 NEI/FDA Endpoints Workshops

Mar 26, 2015 Bethesda, Maryland

Inflammatory Eye Disease

EndpointsLOGO   

Masur Auditorium – NIH Campus
Bethesda, Md.

March 26, 2015

Intraocular inflammation is associated with many complications, including glaucoma, cataracts, macular edema, retinal vascular occlusion and blindness. There is a need for new, more effective corticosteroid sparing anti-inflammatory agents.

This one-day public workshop reviewed clinical trial design considerations for inflammatory eye disease in order to develop strategies for:

  • Improved trial design and endpoints based on current evidence
  • Approaches to classifying and stratifying the patient population
  • Clinically meaningful surrogate or interim endpoints
  • Potentially impactful gaps for research funding      


Advertisement
Phoenix research labs